Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
    (Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
    (Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
    (Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
    Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
    ... The J. R. Simplot Company,s Plant Sciences ... for improving crops, leading to new, better and ...   Innate™ Technology is a patented ... own genes to enhance desirable traits and to ...
    ... SUNNYVALE, Calif., July 12, 2011 Molecular Devices ... discovery & development, life science research, and bioassay/test ... functionality of the SoftMax® Pro Software and prominence ... control ability via an Apple iPad wireless device. ...
    ... New research from the Trudeau Institute may help to ... lives of patients with sepsis. The study was led by ... shows that fibrin, a key product of the blood clotting ... , a gram-negative bacterium that causes sepsis in humans and ...
    Cached Biology Technology:Molecular Devices Enables Intuitive Functionality at Your Fingertips on the Apple iPad with the Latest SoftMax Pro Software 2Trudeau Institute announces a discovery in the fight against sepsis 2
    (Date:4/20/2014)... Most drugs used to treat lung, breast and pancreatic ... Researchers at the University of California, San Diego School ... CD61 on the surface of drug-resistant tumors that appears ... cell-like properties of cancer cells. , The findings, ... Nature Cell Biology , may point to new ...
    (Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
    (Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
    Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
    ... Hormone replacement therapies, or medications containing female hormones ... body, are often prescribed to reduce the effects ... women. Research and clinical trials on hormone replacement ... especially breast cancer, in post-menopausal women who take ...
    ... been elected as a fellow of the American ... organization,s Council on Basic Cardiovascular Sciences., Nguyen, who ... 2005, specializes in cellular engineering. Her research also ... therapies., Liping Tang, interim chairman of the UT ...
    ... Houser, PhD, FAHA, Director of the Cardiovascular Research Center ... studying the heart for nearly three and a half ... to cardiovascular research, work that led to his recent ... Association (AHA) the Basic Cardiovascular Science (BCVS) Council ...
    Cached Biology News:Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds 2Temple's Dr. Steven Houser recognized by the American Heart Association 2Temple's Dr. Steven Houser recognized by the American Heart Association 3
    Polio component type I...
    Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
    ... comprehensive microarray service for systematic discovery ... non-coding RNAs (ncRNAs) using a novel ... which enables highly sensitive and specific ... This comprehensive service includes custom probe ...
    ... LC Sciences provides a comprehensive ... protein kinase substrate (PKS) peptide microarrays ... proteomic scale kinase profiling, quantitative measurement ... discovery research. This comprehensive service includes ...
    Biology Products: